Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BaxAsia: Baxdrostat in Uncontrolled or Resistant Hypertension
jRCT2031230748Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of baxdrostat in hypertension (HTN) and resistant hypertension (RH) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in seated systolic blood pressure at Week 12. Started Apr 2024; status: active, not recruiting.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on jRCT2031230748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230748.